<?xml version="1.0" encoding="UTF-8"?>
<p id="Par10">This open-label, dose-escalation phase I study enrolled treatment-na√Øve patients with pathologically proven locoregionally advanced NPC who sought treatment between November 11, 2011 and September 23, 2013 at Sun Yat-sen University Cancer Center, Guangzhou, China. NPC was staged according to the 7th edition American Joint Committee on Cancer [AJCC] staging system. Patients with histologically confirmed undifferentiated NPC, WHO III and confirmed T3-4N1M0 or T1-4N2-3M0 locoregionally advanced NPC were eligible. Other inclusion and exclusion criteria are described in detail in Additional file 
 <xref rid="MOESM1" ref-type="media">1</xref>: Methods.
</p>
